ArticleStem cell research & therapy2025
Exosomal miR-149 from human umbilical cord mesenchymal stem cells attenuates spinal cord injury-induced blood-spinal cord barrier disruption by suppressing the ET-1/PI3K/Akt signaling pathway.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recent Advances in Hydrogels as Therapeutic Tools for Spinal Cord Injury Regeneration.Tissue engineering and regenerative medicine · 2026Pooled it
- Comparative Evaluation of Exosomes, Mesenchymal Stem Cells, and Nanofat on Cartilage Graft Viability in a Rat Model.Aesthetic plastic surgery · 2026Article
- hUC-MSCs transplantation promotes neurological recovery by ameliorating spinal cord injury and hippocampal synaptic remodeling in female mice.Journal of orthopaedic translation · 2026Article
- Review
- Exosomes as regenerative therapeutics for spinal cord injury: mechanisms and clinical prospects.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSpinal cord injury (SCI) leads to persistent neurological deficits partly by disruption of the blood-spinal cord barrier (BSCB). Small extracellular vesicles (sEVs) from human umbilical cord mesenchymal stem cells (hUC-MSCs) can promote BSCB repair, but their active components remain unclear. This study examined whether miR-149 carried by hUC-MSC-derived sEVs (hUC-MSCs-sEVs) protects the BSCB after SCI by targeting endothelin-1 (ET-1).
methodsHuman brain microvascular endothelial cells (HBMECs) were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) to model barrier injury, and rats underwent a thoracic SCI. hUC-MSCs-sEVs were isolated and loaded with miR-149 mimics or inhibitors. Endothelial cell viability, paracellular permeability (FITC-dextran assay), and junction protein levels (ZO-1, Claudin-5, β-Catenin, Occludin) were measured by viability assays, Western blot, and immunofluorescence. ET-1 levels and PI3K/Akt pathway activation were measured by ELISA and Western blot. In SCI rats, sEVs (with or without the miR-149 inhibitor) were injected; motor function (BBB locomotor score), BSCB permeability (Evans blue/FITC-dextran leakage) and spinal cord histology were evaluated.
resultshUC-MSCs-sEVs were internalized by HBMECs and significantly improved cell survival and barrier function after OGD/R. sEVs treatment restored tight and adherens junction proteins and suppressed OGD/R-induced ET-1 upregulation and PI3K/Akt activation. OGD/R reduced miR-149 expression, which was rescued by sEVs. sEVs loaded with miR-149 mimic further enhanced these protective effects, whereas a miR-149 inhibitor abolished them. Notably, co-administration of an ET-1 receptor antagonist reversed the barrier disruption caused by miR-149 inhibition. In vivo, hUC-MSCs-sEVs treatment improved locomotor recovery and reduced BSCB leakage and tissue damage, whereas miR-149 inhibition abolished these benefits.
conclusionshUC-MSC-derived exosomal miR-149 preserves BSCB integrity and promotes functional recovery after SCI by targeting ET-1 and inhibiting the PI3K/Akt pathway, thereby enhancing junctional protein expression. The miR-149/ET-1 axis may represent a promising therapeutic target for SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.